Viz HCM software is designed to automatically review routine ECGs from the health systems, detect suspected cases of HCM, and alert the appropriate cardiologist
Viz.ai partners with Bristol Myers Squibb for HCM detection. (Credit: jesse orrico on Unsplash)
Viz.ai has signed a multi-year agreement with Bristol Myers Squibb to use an artificial intelligence (AI) algorithm and the Viz HCM provider workflow software to detect and triage patients who need further evaluation for the detection of hypertrophic cardiomyopathy (HCM).
The California-based Viz.ai has filed a de novo request to the US Food and Drug Administration (FDA) for the algorithm as a Software-as-a-Medical-Device (SaMD). The health regulator has accepted the application for review.
Viz HCM software is designed to automatically review routine electrocardiograms (ECGs) from the health systems, detect suspected cases of HCM, and alert the appropriate cardiologist. This will help the physicians to review the ECG in a timely manner and take suitable clinical action.
Viz.ai, which is an artificial intelligence (AI) powered medical imaging company, has plans to integrate the software into the Viz.ai Cardio Suite for US hospitals.
The suite provides a mobile-based ECG viewer with timely AI-based alerts and communication tools to advance cardiac care coordination.
Upon approval, the imaging firm has plans to introduce Viz HCM broadly.
Viz.ai CEO Chris Mansi said: “Hypertrophic cardiomyopathy can be a devastating disease. The agreement with Bristol Myers Squibb gives us the opportunity to enable underdiagnosed and underserved HCM patients to get the care they need from appropriate providers at the right time.
“Incorporating the new HCM module into the Viz Cardio Suite is expected to enhance detection, expedite care, and empower clinicians and patients.”
In a separate development, the company said that it will deploy its Viz RECRUIT platform for optimising patient enrolment for the Pulmonary Embolism—Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial.
Funded by the US National Institutes of Health (NIH), the PE-TRACT trial is said to be a randomised controlled clinical trial of catheter-directed therapy for pulmonary embolism. It will enrol 500 patients across 30-50 locations.
Viz RECRUIT is an AI-powered clinical trial enrolment platform that automates the detection and triage of qualified candidates for a pre-trial review. The trial will use the platform to find, screen, and enrol clinical trial candidates.